Polo GGB
Italian research and service centre (est. 2011) operating laboratories in Siena and Terni focused on genomics, medical genetics, bioinformatics, vector ecology and immunology. Provides clinical genetic diagnostics and molecular/microbiological testing, sequencing (short- and long-read, Sanger), bioinformatics analysis and custom pipelines, monoclonal antibody development and immunoassay services, insectary and controlled-environment vector research, and biosafety and quality management consistent with ISO and regional accreditations. Engages in national and international collaborative research projects.
Industries
Nr. of Employees
small (1-50)
Products
PRS-based predictive genetic test for vulvodynia
Non-invasive genetic test using genotyping, imputation and polygenic risk scoring to assess genetic predisposition to features associated with vulvodynia; intended to support clinical diagnostic pathways and personalised management.
Non-invasive prenatal testing (NIPT)
Prenatal screening for fetal chromosomal alterations and selected DNA abnormalities using non-invasive sampling and genomic analysis.
Hereditary cancer gene testing (BRCA1 / BRCA2)
Testing and analysis of BRCA1 and BRCA2 genes to detect variants associated with increased risk of breast and ovarian cancer, with clinical reporting to support management and counselling.
Third-party comprehensive genomic profiling services (tissue/liquid/hematologic)
Provision or facilitation of comprehensive genomic profiling for oncology via integration with external validated panels for tissue, liquid biopsy and hematologic indications.
PRS-based predictive genetic test for vulvodynia
Non-invasive genetic test using genotyping, imputation and polygenic risk scoring to assess genetic predisposition to features associated with vulvodynia; intended to support clinical diagnostic pathways and personalised management.
Non-invasive prenatal testing (NIPT)
Prenatal screening for fetal chromosomal alterations and selected DNA abnormalities using non-invasive sampling and genomic analysis.
Hereditary cancer gene testing (BRCA1 / BRCA2)
Testing and analysis of BRCA1 and BRCA2 genes to detect variants associated with increased risk of breast and ovarian cancer, with clinical reporting to support management and counselling.
Third-party comprehensive genomic profiling services (tissue/liquid/hematologic)
Provision or facilitation of comprehensive genomic profiling for oncology via integration with external validated panels for tissue, liquid biopsy and hematologic indications.
Services
End-to-end sequencing workflows covering whole-genome, exome, targeted panels, microbial genomes and amplicon sequencing; includes nucleic acid extraction, library preparation (including mate-pair), sequencing, QC and optional bioinformatic analysis.
Custom analysis services for genomics, transcriptomics, single-cell and metagenomics datasets, including development and deployment of analysis pipelines and bespoke algorithms.
Clinical tests including non-invasive prenatal testing (NIPT), hereditary cancer gene testing, comprehensive genomic profiling via third-party integration, and predictive genetic tests with reporting and optional genetic counselling.
Custom monoclonal antibody production and development of immunoassays (microarray-based profiling, automated ELISA, western blot, immunofluorescence) with high-throughput characterisation for specificity and cross-reactivity.
Biosafety management, training and support for contained use of genetically modified organisms and arthropods, supported by certified containment infrastructure and permit management.
Clinical and research microbiology testing including RT-PCR diagnostics for respiratory viruses and microbial profiling services for intestinal and vaginal microbiomes.
End-to-end sequencing workflows covering whole-genome, exome, targeted panels, microbial genomes and amplicon sequencing; includes nucleic acid extraction, library preparation (including mate-pair), sequencing, QC and optional bioinformatic analysis.
Custom analysis services for genomics, transcriptomics, single-cell and metagenomics datasets, including development and deployment of analysis pipelines and bespoke algorithms.
Clinical tests including non-invasive prenatal testing (NIPT), hereditary cancer gene testing, comprehensive genomic profiling via third-party integration, and predictive genetic tests with reporting and optional genetic counselling.
Custom monoclonal antibody production and development of immunoassays (microarray-based profiling, automated ELISA, western blot, immunofluorescence) with high-throughput characterisation for specificity and cross-reactivity.
Biosafety management, training and support for contained use of genetically modified organisms and arthropods, supported by certified containment infrastructure and permit management.
Clinical and research microbiology testing including RT-PCR diagnostics for respiratory viruses and microbial profiling services for intestinal and vaginal microbiomes.
Expertise Areas
- Genomic sequencing and analysis (short- and long-read)
- Bioinformatics and computational genomics
- Clinical genetic diagnostics and prenatal screening
- Predictive genetics and polygenic risk scoring
Key Technologies
- Short-read next-generation sequencing
- Long-read sequencing
- Sanger sequencing
- De novo genome assembly
News & Updates
Five days of scientific presentations showcasing the centre's research activities with participation from researchers and laboratory technicians.
Exhibition presence and dissemination of genetic research relating to vulvodynia and women's health.
Awarded a contribution to expand work on novel mosquito control strategies.
An interview exploring microbiota influence on health and diagnostic frontiers.
Discussion on genetics, prevention and personalized medicine using polygenic risk scores.
Editorial recognition for the organisation's commitment to sustainable development models.
Five days of scientific presentations showcasing the centre's research activities with participation from researchers and laboratory technicians.
Exhibition presence and dissemination of genetic research relating to vulvodynia and women's health.
Awarded a contribution to expand work on novel mosquito control strategies.
An interview exploring microbiota influence on health and diagnostic frontiers.
Discussion on genetics, prevention and personalized medicine using polygenic risk scores.
Editorial recognition for the organisation's commitment to sustainable development models.